Ticker News
$REVB News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
REVB to implement 1-for-7 reverse stock split effective Oct 20 to regain Nasdaq compliance
Revelation Biosciences (REVB) will implement a 1-for-7 reverse stock split effective the morning of Oct 20, 2026 to increase its per-share price and regain compliance with The Nasdaq Capital Market minimum bid requirement; shares will continue trading under the symbol REVB post-split. Warrants, RSUs and options will be proportionally adjusted, fractional shares will be rounded up to whole shares, registered holders need take no action, and broker-held positions will be adjusted per each broker's process.
REVB hires Avance Clinical as CRO for Phase 2/3 TITAN AKI trial
Revelation Biosciences (REVB) has selected Avance Clinical as the CRO for its Phase 2/3 adaptive TITAN study testing Gemini in acute kidney injury and says the study is on track to start later this year. Avance touts global operations and a Renal Center of Excellence that could help recruitment and execution, but the company did not disclose enrollment targets, site count, primary endpoints, or any clinical data/timelines.
REVB grants 108,000 RSUs to three new hires under Nasdaq inducement rule
Revelation Biosciences (REVB) said its compensation committee approved 108,000 restricted stock units to three newly hired non-executive employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over two years in equal quarterly installments (first vesting Oct 15, 2026; final vesting Jul 15, 2028) under the company's 2026 Inducement Plan and will convert into 108,000 shares as they vest.
DFNS subsidiary Rimon advancing deliveries of mobile counter‐UAS launchers for Elbit's Active Defense division
T3 Defense (DFNS) said its subsidiary Rimon completed the first operational mobile counter‐UAS interceptor platform and is executing delivery of the remaining systems to IMI/Elbit Systems' Active Defense division; the trailer‐based platforms integrate independent power, active climate control and a stabilized sensor array for rapid, infrastructure‐independent deployment. This progress targets an urgent IDF need for mobile counter‐drone capability and signals manufacturing execution on a defense integration program, but the company did not disclose contract value, unit counts, or detailed delivery timelines.